Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
10:38pm, Monday, 09'th Mar 2026
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-direct
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
07:30am, Tuesday, 03'rd Mar 2026
Kymera Therapeutics remains focused on pipeline progression despite a Q4 revenue miss and widening net loss, supported by a robust $1.6 billion cash position. R&D investment surged to $316.6 million i
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $2,707,800.00 in Stock
04:23am, Saturday, 28'th Feb 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The shares wer
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
10:35am, Friday, 27'th Feb 2026
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Buy” by Brokerages
01:40am, Friday, 27'th Feb 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has earned a consensus recommendation of "Buy" from the twenty-two ratings firms that are currently covering the firm, Marketbeat Ratings rep
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
03:07pm, Thursday, 26'th Feb 2026
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
10:56am, Thursday, 26'th Feb 2026
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago.
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet
01:37pm, Monday, 23'rd Feb 2026
Baker Bros. Advisors added 2,005,813 shares of Kymera Therapeutics; the estimated transaction value was $135.45 million.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
07:00am, Thursday, 19'th Feb 2026
WATERTOWN, Mass. , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
03:16pm, Tuesday, 17'th Feb 2026
Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the q
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of “Buy” by Brokerages
01:43am, Monday, 02'nd Feb 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings r
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate
11:15am, Friday, 30'th Jan 2026
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
SG Americas Securities LLC Sells 13,633 Shares of Kymera Therapeutics, Inc. $KYMR
04:56am, Sunday, 25'th Jan 2026
SG Americas Securities LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 61.8% during the third quarter, according to the company in its most recent filing with the Se
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:46pm, Tuesday, 13'th Jan 2026
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
07:00am, Tuesday, 13'th Jan 2026
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expecte
